KGFHY News Alert Kingfisher New ADR (KGFHY) 10.5500 09/28/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Kingfisher New ADR (KGFHY) 10.5500 $KGFHY

KGFHY, Has Remained On Naked Short Lists 13 Consecutive Days
M2 - Tue Sep 23, 9:04AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Has Remained On the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. Kingfisher PLC (OTC:KGFHY). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .

KGFHY, Added To Naked Short Lists Today
M2 - Fri Sep 05, 9:18AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Added To the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. Kingfisher PLC (OTC:KGFHY). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .

Office Depot is Now Strong Sell - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 3:52PM CDT
On Mar 18, 2014, Zacks Investment Research downgraded Office Depot to a Zacks Rank #5 (Strong Sell). The shares of this office supplies retailer have tumbled 14.4% year-to-date.

Falling Earnings Estimates Signal Weakness Ahead for Office Depot (ODP) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 7:38AM CDT
Office Depot (ODP) sees falling earnings estimates and significant price decline, as the stock has dropped nearly 11.9% over the past month.

Falling Earnings Estimates Signal Weakness Ahead for Staples (SPLS) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 7:54AM CDT
Staples has witnessed a significant price decline in the past four weeks. The reason is negative trend in earnings estimate revisions. The stock also has seen some pretty dismal trading lately.

Staples Down to Strong Sell - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 2:53PM CDT
Staples (SPLS) missed the Zacks Consensus Estimate in the trailing four quarters by an average of 8.2%.

Why You Need to Pay Attention to Barnes & Noble (BKS) Stock? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 8:00AM CDT
Barnes & Noble has seen its Zacks Rank surge over the past four weeks, moving from Hold territory to its current position as a Strong Buy.

Office Depot (ODP) Falls: Stock Goes Down 5.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 7:44AM CST
Office Depot's shares fell about 6% on the day. This continues the recent downtrend for ODP, as the stock is now down nearly 10% since Feb 24.

PetSmart Q4 Earnings Beat Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 9:16AM CST
PetSmart posted fourth-quarter earnings of $1.28 per share, which easily surpassed the Zacks Consensus Estimate of $1.21 per share and rose 3.2% year over year.

Barnes & Noble Up to Strong Buy on Solid Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 4:47PM CST
On Mar 1, 2014, Zacks Investment Research upgraded Barnes & Noble to a Zacks Rank #1 (Strong Buy) on solid third-quarter fiscal 2014 results.

Should You Get Rid of Steiner (STNR) Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 7:49AM CST
Steiner has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. It could be time to get rid of the security before more losses hit your portfolio.

Office Depot Down to Strong Sell - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 1:45PM CST
On Mar 1, 2014, Zacks Investment Research downgraded Office Depot to a Zacks Rank #5 (Strong Sell).

Falling Earnings Estimates Signal Weakness Ahead for Big 5 Sporting Goods (BGFV) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 7:39AM CST
Big 5 Sporting Goods has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month.

Office Depot (ODP) in Focus: Stock Tumbles 8.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 7:36AM CST
The shares of Office Depot fell nearly 9% on the day. This reverses the recent trend for ODP, as the stock is now up nearly 12% since Feb 3. This supplier of office products and services has seen a flat track record when it comes to current year estimate revisions.

Tractor Supply Enhances Share Buyback Program - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 6:15PM CST
Tractor Supply's Board of Directors authorized the company to buy back additional shares worth $1 billion, taking the total authorization to $2 billion.

Barnes & Noble Up on Talks of G Asset Stake - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 1:00PM CST
Barnes & Noble saw its shares rise 5% after private investment firm, G Asset Management, reportedly offered to buy a majority stake in the company.

Steiner Leisure (STNR) in Focus: Stock Plunged 11.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 7:47AM CST
The shares of Steiner Leisure fell over 11% on the day. This reverses the recent trend for STNR, as the stock is now up nearly 6% since Feb 5. This provider of spa services and personal care products has seen a flat track record when it comes to current year estimate revisions.

1-800-Flowers.com (FLWS) Crumbles: Stock Falls by 6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 8:00AM CST
1-800-Flowers.com Inc. (FLWS) saw a big move last session, reversing the recent trend for FLWS, as the stock is now up more than 5% since Jan 29.

Ulta Salon (ULTA) in Focus: Stock Surges 17.3% - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 16, 7:00AM CDT
Ulta Salon, Cosmetics & Fragrance, Inc. saw its shares surge by more than 17% on the day.

Penny Stocks Trend Analysis Reports On: (OTCQB: TTNP), (OTCQX: KGFHY)
ACCESSWIRE-TNW - Tue Apr 23, 1:31PM CDT
New York (April 23rd, 2013) - Titan Pharmaceuticals Inc. (OTCQB: TTNP) opened at $1.94 and oscillated in the range of $1.84 and $1.99 in the latest trading session. It is at $1.87, down 4.10 percent from its previous close of $1.95. Titan Pharmaceuticals is currently trading below its short term SMA and long term SMA of $1.92 and $1.93 respectively. Titan Pharmaceuticals stock is up 72.07 percent on YTD basis while its 52 weeks gain stands at 176.81 percent.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 34

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 24

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 26

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 35

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading

Top 5 Most Recently Viewed Articles

Man Group PLC Highlights Its Strategic Disclosures on Tritax REIT

Updated Category News Views 148

Strategic Position Disclosure by Man Group PLC Man Group PLC is actively sharing its significant interests in the securities market, particularly focusing on its involvement with Tritax Big Box REIT plc. As a key player in the investment landscape, this disclosure marks an important step for the company regarding its strategic holdings. Key Information Pertaining to the...

Continue Reading
TalentLMS and Epignosis Lead the Way in GDPR Compliance

Updated Category News Views 720

TalentLMS and Epignosis Set the Standard for GDPR Compliance TalentLMS, along with its parent company Epignosis, has continuously led the way in providing a fully compliant Learning Management System (LMS) with regards to the General Data Protection Regulation (GDPR). Recent developments affirm that TalentLMS remains the only LMS globally to uphold its commitment to this...

Continue Reading
Zillow and Esusu Forge New Path to Boost Renters' Credit Scores

Updated Category News Views 283

Building Credit for Renters with Zillow and Esusu The recent collaboration between Zillow and Esusu marks a significant step towards empowering renters across the country to build their credit. This partnership allows any renter to report their on-time rent payments, significantly enhancing their credit profiles, for just $20 a year. How the Partnership Works Starting...

Continue Reading
iCrowdNewswire Leverages DeepL for Enhanced Global Communication

Updated Category News Views 121

iCrowdNewswire Enhances Multilingual Capabilities iCrowdNewswire, a prominent international press release distribution company, has embarked on a transformative journey to improve its multilingual services through the introduction of the DeepL API. The integration of DeepL's cutting-edge language AI technology has significantly boosted iCrowdNewswire’s ability to...

Continue Reading
Celebrating Excellence: Top Surgeons Recognized in Endocrine Care

Updated Category News Views 82

Exceptional Recognition for Leading Surgeons in Endocrine Surgery Dr. Jim Norman and Dr. Gary Clayman Acknowledged as Premier Specialists The Hospital for Endocrine Surgery is proud to announce that two of its distinguished surgeons, Dr. Jim Norman and Dr. Gary Clayman, have been honored in the prestigious Castle Connolly Top Doctors list for 2025. This remarkable...

Continue Reading